- Home
- MG vs LYEL Comparison
MG vs LYEL Comparison
Compare MG & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MG | LYEL |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.4M | 369.4M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MG | LYEL |
|---|---|---|
| Price | $11.92 | $24.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.67 |
| AVG Volume (30 Days) | ★ 178.8K | 36.7K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.33 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $715,300,000.00 | $41,000.00 |
| Revenue This Year | $1.23 | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $21.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.06 | $7.65 |
| 52 Week High | $13.43 | $25.20 |
Technical Indicators
Market Signals| Indicator | MG | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 77.95 |
| Support Level | $11.40 | $16.95 |
| Resistance Level | $12.10 | $18.13 |
| Average True Range (ATR) | 0.56 | 1.69 |
| MACD | -0.09 | 0.74 |
| Stochastic Oscillator | 37.83 | 90.24 |
Price Performance
Historical ComparisonAbout MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.